Race Oncology Half-Year Financial Report to 31 December 2021
MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene
MD Anderson Cancer Center Collaborators Publish Peer Reviewed AML Preclinical Study on Zantrene
23 February 2022 – Race Oncology Limited (“Race”) is pleased to announce a researcherteam, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MDAnderson Cancer Center (Texas, USA), have identified a...
Appointment of Chief Financial Officer
Appointment of Chief Financial Officer
31 January 2022 – Race Oncology Limited (“Race”) is pleased to announce theappointment of Christina Manfre, as Chief Financial Officer. Christina is employed as a partner at PKF Sydney Pty Ltd and will via...
Q2 FY 2022 Quarterly Activity Report
Race Receives $708k R&D Tax Refund
Race Receives $708k R&D Tax Refund
18 January 2022 – Race Oncology Limited (“Race”) is pleased to announce that it hasreceived a $707,557 Research & Development Tax Incentive Refund from the AustralianTaxation Office for the financial year ending 30 June...
Race raises full $29.7 million in heavily oversubscribed Share Purchase Plan
Race raises full $29.7 million in heavily oversubscribed Share Purchase Plan
21 December 2021 – Race Oncology Limited (“Race”) is pleased to announce that its Share Purchase Plan (SPP) has closed heavily oversubscribed with $43.9m received in applications from 2,340 shareholders. In line with the...
Race Extends Heart Protection Collaboration with University of Newcastle
Race Extends Heart Protection Collaboration with University of Newcastle
10 December 2021 – Race Oncology Limited (“Race”) is pleased to announce it has extended and expanded its collaborative cardio-protective research program for Zantrene® (bisantrene dihydrochloride) with eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov...
Expanded Heart Protection Discovery for Zantrene
Expanded Heart Protection Discovery for Zantrene
08 December 2021 – Race Oncology Limited (“Race”) is pleased to share additional interim results from the Zantrene® (bisantrene dihydrochloride) preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov...
Breakthrough Chemotherapy Heart Protection Discovery for Zantrene
Breakthrough Chemotherapy Heart Protection Discovery for Zantrene
22 November 2021 – Race Oncology Limited (“Race”) is pleased to share interim results from the Zantrene® preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo,...
Race Initiates Strategic Zantrene Formulation Collaboration with the University of Wollongong
Race Initiates Strategic Zantrene Formulation Collaboration with the University of Wollongong
8 November 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a strategic collaborative research agreement with the University of Wollongong (UOW) to undertake preclinical evaluation of new...
